Pulished Date October, 2018
ID: 1114
Share on
Share on

Europe Antibodies Market by product type - (Monoclonal Antibodies, Polyclonal Antibodies, Anti-body drug complexes), by Indication - (Cancer, Auto immune diseases, Infectious diseases, Cardiovascular diseases, CNS disorders, others), by End user (Hospitals/clinics, Research institute, Diagnostics laboratories), by Application (Medical, Experimental) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2018-2023)

Pulished: October, 2018
ID: 1114
Pages: 145

Efficient resource to therapy of complex disorders with minor side-effects has enhanced the growth of antibodies based therapeutics against chemical drugs.

Europe Antibodies Market was worth $ 31.78 Billion in 2018 and estimated to reach $ 54.55 Billion by the end of 2023 with a growing potential of 11.41 %.

Antibodies (Ab’s) are also known as an immunoglobulin (Ig) that are large, Y-shaped protein produced by plasma cells which are used by the immune system to detect, identify and neutralize pathogens such as Viruses and bacteria. The antibody recognizes harmful agent, called an antigen, via the Fab's variable region. Depending on the type of antigen, the binding may inhibit the biological process causing the disease or could activate macrophages to destroy the foreign substance.

Europe Antibodies market is driven by innovative products, increasing rate of adoption to therapeutic antibodies in cost-sensitive markets, rise in chronic illnesses due to population shift and increasing longevity, quick approval for breakthrough therapies by regulatory authorities, and adoption of diagnostic antibodies. High cost of treatment and side effects associated with antibodies treatment are the restraints that are affecting the growth of the market.

Based on product type, the market is segmented into Monoclonal Antibodies, Polyclonal Antibodies, and Anti-body drug complexes. The monoclonal antibodies are further segmented into Murine, Chimeric, Humanized, and Human. The polyclonal antibodies are further categorized into Type I, Type II, Type III, Type IV, Type V, Type VI, Type VII, Type VIII. The Antibody-Drug Complexes are further segmented into Immunogen Technology, Seattle Genetics Technology, and Immunomedics Technology.

Based on Indication, the market is segmented into Cancer, Auto immune diseases, Infectious diseases, cardiovascular diseases, and CNS disorders, others (Inflammatory, Microbial Diseases, & Other). Based on end users, the market is segmented into Hospitals/Clinics, Research institute, Diagnostics laboratories.

Based on Application, the market is segmented into Medical, Experimental. The Experimental segment is further categorized into Western blot, ELISA, Radioimmune Assays, immunofluorescence, others (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry).Based on Geography, the Europe Antibodies market is analysed under various regions namely U.K, Germany, France, Italy and Spain.

Some of the Key players operating in Europe Antibodies market are Merck KGaA, Novartis AG, Pfizer Inc., ThermoFisher Scientific Inc., Eli Lilly and company, BioMerieux, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Qiagen N.V.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Product Type                       

                                5.1.1 Monoclonal Antibodies     

                                                5.1.1.1 Murine

                                                5.1.1.2 Chimeric

                                                5.1.1.3 Humanized

                                                5.1.1.4 Human 

                                5.1.2 Polyclonal Antibodies         

                                                5.1.2.1 Type I

                                                5.1.2.2 Type II

                                                5.1.2.3 Type III

                                                5.1.2.4 Type IV

                                                5.1.2.5 Type V

                                                5.1.2.6 Type VI

                                                5.1.2.7 Type VII

                                                5.1.2.8 Type VIII

                                5.1.3 Antibody-Drug Complexes

                                                5.1.3.1 Immunogen Technology

                                                5.1.3.2 Seattle Genetics Technology

                                                5.1.3.3 Immunomedics Technology

                5.2 By Indication                              

                                5.2.1 Cancer      

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders       

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)             

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 Europe                         

                                6.1.1 Introduction           

                                6.1.2 U.K             

                                6.1.3 Spain         

                                6.1.4 Germany 

                                6.1.5 Italy           

                                6.1.6 France      

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Antibodies Development                         

                                7.5.1 Targeted Therapies             

                7.6 Promising Antibodies in Pipeline                       

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Antibodies                            

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Merck KGaA (Germany)                        

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 bioMerieux (France)               

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.9 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.10 Qiagen N.V. (Netherlands)                

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Antibodies Market By Product type, From 2018-2023 ( USD Billion )
  2. Europe Monoclonal Antibodies Market By Region, From 2018-2023 ( USD Billion )
  3. Europe Polyclonal Antibodies Market By Region, From 2018-2023 ( USD Billion )
  4. Europe Antibody-Drug complexes Market By Region, From 2018-2023 ( USD Billion )
  5. Europe Antibodies Market By Indication, From 2018-2023 ( USD Billion )
  6. Europe Cancer Market By Region, From 2018-2023 ( USD Billion )
  7. Europe Auto immune diseases Market By Region, From 2018-2023 ( USD Billion )
  8. Europe infectious diseases Market By Region, From 2018-2023 ( USD Billion )
  9. Europe Cardiovascular diseases Market By Region, From 2018-2023 ( USD Billion )
  10. Europe CNS disorders Market By Region, From 2018-2023 ( USD Billion )
  11. Europe Antibodies Market By End users, From 2018-2023 ( USD Billion )
  12. Europe Hospitals Market By Region, From 2018-2023 ( USD Billion )
  13. Europe Research institute Market By Region, From 2018-2023 ( USD Billion )
  14. Europe Diagnostics laboratories Market By Region, From 2018-2023 ( USD Billion )
  15. Europe Antibodies Market By Application, From 2018-2023 ( USD Billion )
  16. Europe Medical Market By Region, From 2018-2023 ( USD Billion )
  17. Europe Experimental Market By Region, From 2018-2023 ( USD Billion )
  18. U.K. Antibodies Market By Product type, From 2018-2023 ( USD Billion )
  19. U.K. Antibodies Market By Indication, From 2018-2023 ( USD Billion )
  20. U.K. Antibodies Market By End users, From 2018-2023 ( USD Billion )
  21. U.K. Antibodies Market By Application, From 2018-2023 ( USD Billion )
  22. Germany Antibodies Market By Product type, From 2018-2023 ( USD Billion )
  23. Germany Antibodies Market By Indication, From 2018-2023 ( USD Billion )
  24. Germany Antibodies Market By End users, From 2018-2023 ( USD Billion )
  25. Germany Antibodies Market By Application, From 2018-2023 ( USD Billion )
  26. France Antibodies Market By Product type, From 2018-2023 ( USD Billion )
  27. France Antibodies Market By Indication, From 2018-2023 ( USD Billion )
  28. France Antibodies Market By End users, From 2018-2023 ( USD Billion )
  29. France Antibodies Market By Application, From 2018-2023 ( USD Billion )
  30. Italy Antibodies Market By Product type, From 2018-2023 ( USD Billion )
  31. Italy Antibodies Market By Indication, From 2018-2023 ( USD Billion )
  32. Italy Antibodies Market By End users, From 2018-2023 ( USD Billion )
  33. Italy Antibodies Market By Application, From 2018-2023 ( USD Billion )
  34. Spain Antibodies Market By Product type, From 2018-2023 ( USD Billion )
  35. Spain Antibodies Market By Indication, From 2018-2023 ( USD Billion )
  36. Spain Antibodies Market By End users, From 2018-2023 ( USD Billion )
  37. Spain Antibodies Market By Application, From 2018-2023 ( USD Billion )
  38. Europe Antibodies Market By Monoclonal Antibodies, From 2018-2023 ( USD Million )
  39. Europe Murine Market By Region, From 2018-2023 ( USD Million )
  40. Europe Chimeric Market By Region, From 2018-2023 ( USD Million )
  41. Europe Humanized Market By Region, From 2018-2023 ( USD Million )
  42. Europe Human Market By Region, From 2018-2023 ( USD Million )
  43. U.K. Antibodies Market By Monoclonal Antibodies, From 2018-2023 ( USD Million )
  44. Germany Antibodies Market By Monoclonal Antibodies, From 2018-2023 ( USD Million )
  45. France Antibodies Market By Monoclonal Antibodies, From 2018-2023 ( USD Million )
  46. Italy Antibodies Market By Monoclonal Antibodies, From 2018-2023 ( USD Million )
  47. Spain Antibodies Market By Monoclonal Antibodies, From 2018-2023 ( USD Million )
  48. Europe Antibodies Market By Polyclonal Antibodies, From 2018-2023 ( USD Million )
  49. Europe Type I Market By Region, From 2018-2023 ( USD Million )
  50. Europe Type II Market By Region, From 2018-2023 ( USD Million )
  51. Europe Type III Market By Region, From 2018-2023 ( USD Million )
  52. Europe Type IV Market By Region, From 2018-2023 ( USD Million )
  53. Europe Type V Market By Region, From 2018-2023 ( USD Million )
  54. Europe Type VI Market By Region, From 2018-2023 ( USD Million )
  55. Europe Type VII Market By Region, From 2018-2023 ( USD Million )
  56. Europe Type VIII Market By Region, From 2018-2023 ( USD Million )
  57. U.K. Antibodies Market By Polyclonal Antibodies, From 2018-2023 ( USD Million )
  58. Germany Antibodies Market By Polyclonal Antibodies, From 2018-2023 ( USD Million )
  59. France Antibodies Market By Polyclonal Antibodies, From 2018-2023 ( USD Million )
  60. Italy Antibodies Market By Polyclonal Antibodies, From 2018-2023 ( USD Million )
  61. Spain Antibodies Market By Polyclonal Antibodies, From 2018-2023 ( USD Million )
  62. Europe Antibodies Market By Antibody-Drug Complexes, From 2018-2023 ( USD Million )
  63. Europe Immunogen Technology Market By Region, From 2018-2023 ( USD Million )
  64. Europe Seattle Genetics Technology Market By Region, From 2018-2023 ( USD Million )
  65. Europe Immunomedics technology Market By Region, From 2018-2023 ( USD Million )
  66. U.K. Antibodies Market By Antibody-Drug Complexes, From 2018-2023 ( USD Million )
  67. Germany Antibodies Market By Antibody-Drug Complexes, From 2018-2023 ( USD Million )
  68. France Antibodies Market By Antibody-Drug Complexes, From 2018-2023 ( USD Million )
  69. Italy Antibodies Market By Antibody-Drug Complexes, From 2018-2023 ( USD Million )
  70. Spain Antibodies Market By Antibody-Drug Complexes, From 2018-2023 ( USD Million )
  71. Europe Antibodies Market By Experimental, From 2018-2023 ( USD Million )
  72. Europe Western Blot Market By Region, From 2018-2023 ( USD Million )
  73. Europe ELISA Market By Region, From 2018-2023 ( USD Million )
  74. Europe Radioimmune Assays Market By Region, From 2018-2023 ( USD Million )
  75. Europe immunoflourscence Market By Region, From 2018-2023 ( USD Million )
  76. U.K. Antibodies Market By Experimental, From 2018-2023 ( USD Million )
  77. Germany Antibodies Market By Experimental, From 2018-2023 ( USD Million )
  78. France Antibodies Market By Experimental, From 2018-2023 ( USD Million )
  79. Italy Antibodies Market By Experimental, From 2018-2023 ( USD Million )
  80. Spain Antibodies Market By Experimental, From 2018-2023 ( USD Million )

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients